Savara, Inc. (SVRA)
5.565
-0.02
(-0.45%)
USD |
NASDAQ |
Aug 24, 16:00
5.565
0.00 (0.00%)
After-Hours: 20:00
Savara Enterprise Value : 1.006B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 1.006B |
| August 20, 2026 | 985.02M |
| August 19, 2026 | 1.004B |
| August 18, 2026 | 960.37M |
| August 17, 2026 | 960.37M |
| August 14, 2026 | 962.42M |
| August 13, 2026 | 939.83M |
| August 12, 2026 | 1.028B |
| August 11, 2026 | 1.001B |
| August 10, 2026 | 1.034B |
| August 07, 2026 | 1.055B |
| August 06, 2026 | 1.047B |
| August 05, 2026 | 989.12M |
| August 04, 2026 | 968.58M |
| August 03, 2026 | 952.15M |
| July 31, 2026 | 978.85M |
| July 30, 2026 | 995.29M |
| July 29, 2026 | 941.88M |
| July 28, 2026 | 952.15M |
| July 27, 2026 | 972.69M |
| July 24, 2026 | 989.12M |
| July 23, 2026 | 1.038B |
| July 22, 2026 | 1.018B |
| July 21, 2026 | 1.057B |
| July 20, 2026 | 985.02M |
| Date | Value |
|---|---|
| July 17, 2026 | 991.18M |
| July 16, 2026 | 991.18M |
| July 15, 2026 | 1.051B |
| July 14, 2026 | 1.026B |
| July 13, 2026 | 1.036B |
| July 10, 2026 | 1.096B |
| July 09, 2026 | 1.149B |
| July 08, 2026 | 1.168B |
| July 07, 2026 | 1.133B |
| July 06, 2026 | 1.131B |
| July 02, 2026 | 1.135B |
| July 01, 2026 | 1.102B |
| June 30, 2026 | 1.123B |
| June 29, 2026 | 1.063B |
| June 26, 2026 | 1.036B |
| June 25, 2026 | 1.063B |
| June 24, 2026 | 1.022B |
| June 23, 2026 | 1.012B |
| June 22, 2026 | 993.35M |
| June 18, 2026 | 954.41M |
| June 17, 2026 | 929.82M |
| June 16, 2026 | 913.43M |
| June 15, 2026 | 919.57M |
| June 12, 2026 | 905.23M |
| June 11, 2026 | 907.28M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 202.61B |
| Insmed, Inc. | 27.04B |
| United Therapeutics Corp. | 19.24B |
| Vertex Pharmaceuticals, Inc. | 132.96B |
| SELLAS Life Sciences Group, Inc. | 2.984B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -40.23M |
| Total Expenses (Quarterly) | 40.23M |
| EPS Diluted (Quarterly) | -0.1587 |
| Earnings Yield | -10.36% |
| Normalized Earnings Yield | -10.36 |